Actio Biosciences, Inc. and Jazz Pharmaceuticals
Jazz Pharmaceuticals completes acquisition of Actio Biosciences for $820 million
Company-confirmed: reported in the company's own SEC filing
Latest update Sep 15, 2026, 1:06 PM ET
- ✓Announced
- ✓Live
- ✓Closed
Acquirer
Jazz PharmaceuticalsJAZZTarget
Actio Biosciences, Inc.Not US-listed- Deal value
- $820M
- as stated in the filing
- Offer
- Not disclosed
- Premium
- N/A
- Shown only for a signed all-cash price per share
- Expected close
- fourth quarter of 2026
- merger
Deal dates
- Announced
- Aug 10, 2026
- date written in the filing
- Closed
- Sep 15, 2026
- date written in the filing · 36 days after the announcement
Closed: the filing says the transaction was completed. Dates come from the company's Form 8-K; when a filing states no date for an event, the day the SEC accepted it is used and says so. An expected close is the company's own wording, not a date OQRO predicts.
Share prices around the disclosure
Daily closes, each set to 100 on the first day shown. The dashed lines mark the session that first reflects each public event.
